A new study suggests men with certain MSH2 and MSH6 mutations have higher risks of prostate cancer and may be candidates for PSA screening.
Bancroft et al. Lancet Oncol. 2021 Nov. PMID: 34678156. Social media post
December 17th, 2021. Available at: https://tinyurl.com/post121721